SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ImmunityBio converts from Immunomedics
IBRX 2.415-6.4%3:59 PM EDT
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: luckydog88 who wrote (1139)8/18/2025 2:19:02 PM
From: bobbseytwins20012 Recommendations

Recommended By
Fitzhughlaw
jargonweary

  Read Replies (1) of 1216
 
We agree with your analysis, and share your frustrations. We are hanging our hats on the fact that IBRX has an approved and expandable therapy in Anktiva and that PSS has a vested interest in not losing most of his fortune. And that is why we think he will act in his (and our) self interest when the time is right for him or when he is forced. We are simply passengers on the Anktiva ride.....But it's still frustrating and we wish he would treat his shareholders right. So far, no good.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News